Gossamer Bio, Inc. (GOSS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

9.80-0.14 (-1.41%)

At close: 4:00PM EST

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bullishpattern detected

Inside Bar (Bullish)

View all chart patterns

Performance Outlook

Previous Close	9.94
Open	9.92
Bid	0.00 x 800
Ask	0.00 x 3000
Day's Range	9.72 - 9.96
52 Week Range	7.52 - 16.79
Volume	796,508
Avg. Volume	775,742

Market Cap	744.094M
Beta (5Y Monthly)	1.29
PE Ratio (TTM)	N/A
EPS (TTM)	-3.55
Earnings Date	Feb 25, 2021
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	21.13

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

All

News

Press Releases

Research Reports

Business Wire
Gossamer Bio Announces Fourth Quarter and Full-Year 2020 Financial Results and Provides Business Update
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced its financial results for the fourth quarter and year ended December 31, 2020 and provided a business update.
- Travere Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results
  GlobeNewswire
- Seres Therapeutics Announces Achievement of Target Enrollment in SER-287 Phase 2b ECO-RESET Study for Ulcerative Colitis
  Business Wire
Business Wire
Gossamer Bio to Announce Fourth Quarter and Full-Year 2020 Financial Results and Host Conference Call and Webcast on February 25, 2021
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will report its fourth quarter and full-year 2020 financial results on Thursday, February 25, 2021.
Business Wire
Gossamer Bio to Host Webcast Focused on its Inflammatory Bowel Disease Program, GB004, on February 18, 2021
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will host a conference call and webcast for investors and analysts on Thursday, February 18, 2021 at 11:00am ET to discuss GB004, its oral HIF-1α stabilizer for the treatment of inflammatory bowel disease (IBD), including ulcerative colitis (UC).